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Production of thyroid-stimulating hormone receptor (TSHR) antibodies represents the 
hallmark of Graves’ disease (GD) pathogenesis. Thus, for more than two decades the 
TSHR gene has been at the center of studies intended to elucidate its contribution 
to disease pathology. The advent of genome-wide association technology allowed to 
establish a strong association of the TSHR gene with GD. Subsequent fine-mapping 
studies narrowed the disease-susceptibility region to a 40  kb sequence in intron 1, 
where at least five GD-associated SNPs in tight linkage disequilibrium were identified. 
The current challenge is to understand the functional mechanisms by which these poly-
morphisms modify physiological processes and trigger disease. The aim of this review is 
to summarize the current knowledge on the role of the TSHR gene in GD pathogenesis, 
which has been gained through linkage and association studies, as well as to discuss 
the emerging mechanisms underlying biological implications of TSHR variants in the 
development of GD.
Keywords: Graves’ disease, thyroid-stimulating hormone receptor, single nucleotide polymorphisms, GwAS, 
histone modifications
inTRODUCTiOn
Autoimmune thyroid diseases (AITD), including Graves’ disease (GD) and Hashimoto’s thyroiditis 
(HT), affect 2–5% of the general population, representing the most frequent autoimmune conditions 
(1, 2). Similar to other complex autoimmune diseases, it is believed that AITD occur when interactions 
of genetic susceptibility factors with environmental triggers lead to loss of immune self-tolerance at 
peripheral and central levels (3). During the last three decades, several approaches from linkage 
and association studies to candidate genes analysis and whole-genome screening enabled significant 
progress in the identification of genes that confer susceptibility to AITD. These genes are broadly 
grouped as either immune-modulating genes (including the HLA family, CD40, CD25, FOXP3, 
PTPN22) or thyroid-specific genes [thyroid-stimulating hormone receptor (TSHR) and TG].
The TSHR is unique among these susceptibility genes because it encodes for a protein that is 
both responsible for the clinical manifestations of the disease and is the direct target of autoimmune 
response in GD. The TSHR gene, located on chromosome 14q31, consists of 10 exons and encodes 
for a G protein-coupled receptor that plays a central role in the regulation of thyroid development, 
growth, and function. Indeed, TSHR-stimulating antibodies (TSAbs) are present in nearly all cases 
of GD, and severity of the disease correlates with TSAbs levels (4). Moreover, compelling evidence 
has correlated TSHR gene variants exclusively with GD susceptibility and not with HT development 
(5, 6). The aim of this review is to summarize the current knowledge of the role of TSHR gene in GD 
pathology, gained through linkage analysis, association, and functional studies.
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LinKAGe STUDieS
Whole-genome linkage is a powerful technique for screening 
the human genome for major susceptibility genes, without any 
previous assumption on the mechanisms of genetic susceptibility 
to the disease. It is based on the principle that the probability of 
recombination between two loci is directly related to the genetic 
distance between them. Thus, if two loci comprising a polymor-
phism and a disease-related gene are close to each other on a 
chromosome, the alleles of the polymorphic loci will cosegregate 
with the disease within affected families because the likelihood 
of recombination between the polymorphism and the disease-
related gene is very low. Single nucleotide polymorphisms (SNPs) 
and microsatellites are the main genetic polymorphisms screened 
in the linkage studies (7, 8).
Several linkage studies intended to detect GD-specific loci 
had limited success in demonstrating significant linkage (as well 
as association) of the TSHR gene with GD (9–13). However, 
Tomer et al. identified a large region of linkage on chromosome 
14q31 containing the TSHR locus in whole-genome linkage 
studies in multiplex, multigenerational AITD families (14–17). 
They identified a locus, designated Graves’ disease 1 (GD-1) 
that included TSHR gene, as well as other potential candidate 
genes—such as estrogen receptor 2, deiodinase type 2, and 
immunoglobulin heavy locus (14, 17). Later, fine-mapping 
analysis by Tomer et al. confirmed that the susceptibility gene 
in the GD-1 locus was indeed the TSHR gene, even though a 
second gene in this locus, NRXN3, was also identified as a major 
GD gene (18).
ASSOCiATiOn STUDieS
Reflecting the importance of TSHR for GD pathogenesis, TSHR 
was the first non-MHC gene to be tested for association with 
the disease. Three germline missense mutations were initially 
described in patients with GD and proposed to be associated 
with the disease (19, 20): a substitution of aspartic acid (D) for 
histidine (H) in position 36 (D36H); a substitution of a proline 
(P) for threonine (T) in position 52 (P52T), and a substitution of 
aspartic acid (D) for glutamic acid (E) in position 727 (D727E). 
Two of these three mutations, D36H and P52T, are located in the 
putative ligand binding region of the extracellular domain of the 
TSHR, while the third one, D727E lies within the intracellular 
domain of the receptor.
However, studies regarding association of these SNPs with GD 
were contradictory. In 1995, Bahn and colleagues were first to 
report the association of the P52T polymorphism with AITD in 
female population (21), but in a subsequent study Watson et al. 
found no differences in the distribution of this polymorphism 
in GD patients as compared with autoimmune hypothyroidism 
patients and control individuals (22). Several subsequent studies 
reached inconsistent results, thus a clear association of P52T or 
D36H with GD was not confirmed (23–25). In 1999, Gabriel et al. 
reported that the C to G transition in the TSHR 727 codon lead-
ing to D727E variant has an increased frequency in patients with 
non-autoimmune thyroiditis (26), and this association was also 
recently reported in a small Turkish population (27). However, 
the D727E association with non-autoimmune thyroiditis was 
not supported by studies in large series of European Caucasian 
patients (28). The association of D727E polymorphism with auto-
immune thyroiditis was supported by data from a case–control 
study in Russian populations (29) but was not confirmed in US 
Caucasian patients (13, 26). Finally, Tomer group performed a 
case–control study and meta-analysis combining the data from 
three independent studies and showed a very week association of 
D727E polymorphism and GD (13).
To date, no compelling evidence exists to support a role of 
these three TSHR polymorphisms in GD pathogenesis. Given the 
frequency of these variants in general population, it is believed 
that they are common polymorphisms, not implicated in devel-
opment of GD (20). The lack of consistency among completed 
studies could be the consequence of ethnic differences, selection 
bias, and population stratification.
In the last decade, the association of common genetic 
variants with complex diseases was significantly facilitated by 
the increased ability to measure genetic variability of hundreds 
of markers in large cohorts of individuals. The advent of genome-
wide association technology applied to large case–control studies 
allowed identification of disease-associated variants and their 
contribution to disease susceptibility. Applying this technology 
to AITD resulted in identification of new disease-associated loci, 
including TSHR, and provided unique insights into their genetic 
contribution to disease pathology. Table 1 summarizes the main 
studies conducted over the years that established association of 
the TSHR gene with GD risk.
In 2005, Dechairo et  al. analyzed 40 SNPs mapping to a 
600-kb sequence encompassing the TSHR gene in a Caucasian 
cohort of 1,056 AITD patients and 971 controls. They identi-
fied a haplotype associated with GD (OR =  1.7), but not with 
autoimmune hypothyroidism, and concluded that TSHR is a 
GD-specific susceptibility locus (5). Importantly, rs2268458, 
the SNP showing the strongest association (OR = 1.3) with GD 
mapped to TSHR intron 1; the association was confirmed in a 
large UK Caucasian cohort (5). The same year, an independent 
case–control study conducted in 400 patients with AITD and 
238 controls of Japanese descent found several adjacent SNPs 
in TSHR intron 7 significantly associated with GD, but not with 
autoimmune hypothyroidism, suggesting that polymorphisms in 
the TSHR intron 7 could contribute to GD susceptibility (32). 
However, subsequent association studies conducted over several 
years in Caucasian populations could not replicate the association 
of TSHR intron 7 SNPs with GD (6, 35, 41).
In 2009, Brand et al. interrogated a panel of 98 SNPs spanning 
an 800 kb region of the TSHR gene in a cohort of 768 GD subjects 
and 768 controls (6). The SNPs showing the strongest association 
with GD, rs179247 (OR =  1.53), and rs12101255 (OR =  1.55) 
were located in TSHR intron 1 (6). The association of the TSHR 
intron 1 SNPs with GD was validated by further studies of several 
Caucasian (34, 35) and Brazilian (41) populations. In 2011, a large 
GWAS conducted by the China Consortium of the Genetics of 
Autoimmune Thyroid Disease in 1,536 individuals with GD and 
1,516 controls confirmed TSHR as a primary susceptibility locus 
for GD by finding a robust association (OR = 1.35) of an intron 
1 SNP (rs12101261) with the disease (36). Two years later, the 
TABLe 1 | Association studies of thyroid-stimulating hormone receptor 
(TSHR) gene with Graves’ disease risk.
Studies Cases 
(n)
Population Main 
polymorphisms 
found
Associated 
TSHR 
region
Cuddihy et al. (30) 91 Caucasian 
(USA)
rs2234919 
(P52T)
Exon 1
Akamizu et al. (31) 186 Japanese TSHR-AT Intron 2
Chistiakov et al. 
(29)
78 Russian rs1991517 
(D727E)
Exon 10
Ho et al. (24) 164 Chinese, 
Malays, 
Indians
rs2239610 Intron 1
Hiratani et al. (32) 250 Japanese rs2268475, 
rs3783938
Intron 7, 
intron 8
Dechairo et al. (5) 1,422 Caucasian 
(UK)
rs2268458 Intron 1
Burton et al. (33) 1,000 Caucasian 
(UK)
rs3783941 Intron 8
Yin et al. (34) 200 Caucasian 
(women only)
rs2268458 Intron 1
Brand et al. (6) 768 Caucasian 
(UK)
rs179247, 
rs12101255
Intron 1
Ploski et al. (35) 3,258 Caucasian 
(Poland, UK)
rs179247, 
rs12101255
Intron 1
Chu et al. (36) 5,530 Chinese rs12101261 Intron 1
Colobran et al. (37) 137 Caucasian 
(Spanish)
rs179247 Intron 1
Liu et al. (38) 404 Chinese rs12101255, 
rs179247
Intron 1
Inoue et al. (39) 112 Japanese rs179247 Intron 1
Tomer et al. (18) 225 Caucasian 
(USA)
rs2284720 Intron 1
Liu et al. (40) 5,368 Chinese rs12101261, 
rs179243
Intron 1
Bufalo et al. (41) 279 Brazilian rs179247, 
rs12885526
Intron 1
Fujii et al. (42) 180 Japanese rs4411444 Intron 1
Lombardi et al. (43) 333 Caucasian 
(Italy)
rs179247, 
rs3783948, 
rs12101255
Intron 1
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same group conducted a fine-mapping study that established 
the association of two independent TSHR intron 1 susceptibility 
variants, rs1201261 and rs179243 in a large Chinese Han popula-
tion (40). Noticeable, rs1201261 and rs179243 are in tight linkage 
disequilibrium (LD) with rs12101255 (r2 = 1.0) and rs2268458 
(r2 = 0.91), respectively, which were found associated with GD in 
Caucasian populations of European descent (6).
Recently, three meta-analysis studies intended to refine the 
effects of rs179247 and rs12101255 SNPs on GD susceptibility 
concluded that there is a significant association between these 
SNPs in TSHR intron 1 and GD (44–46).
Collectively, the association studies conducted during the last 
decade provided compelling evidence and established TSHR as 
a GD-specific susceptibility locus. Furthermore, fine-mapping 
studies pointed to a unique susceptibility region located in TSHR 
intron 1, where at least five GD-associated SNPs were mapped: 
rs179247, rs2284720, rs12101255, rs12101261, and rs2268458 
(Figure 1A).
FUnCTiOnAL ReLevAnCe OF TSHR 
POLYMORPHiSMS
The discovery of the TSHR GD-associated SNPs within a non-
protein coding gene region raised questions about their potential 
effect on gene function, as well as their impact on disease pathol-
ogy. Since DNA variants located in intronic or intergenic sites 
can impact different layers of gene regulation, identification of 
their functional role is often difficult. For example, by modifying 
the DNA sequence, non-coding SNPs can affect transcriptional 
factors’ (TFs) binding and thus modulate gene transcription; they 
can also impact RNA splicing and stability as well as posttransla-
tion events (48). In addition, DNA variants can modulate, directly 
or indirectly, epigenetic marks such as DNA methylation, histone 
modifications, and microRNAs activity (48, 49). Recently, it has 
been shown that differential binding of TFs at sites harboring 
DNA variants triggers specific histone modifications, which can 
modify gene expression and determine the phenotype (50–52). 
In the case of disease-associated SNPs, such genetic–epigenetic 
interactions can increase the risk or even trigger disease in certain 
individuals.
To date, studies aimed to unveil the mechanistic role of TSHR 
intron 1 variants in gene function and thyroid autoimmunity 
pointed to two distinct mechanisms. The first proposed mecha-
nism supports a role of the disease-associated SNPs in defective 
peripheral tolerance; the second mechanism supports the concept 
that the disease-associated intron 1 SNPs cause reduced intra-
thymic TSHR expression, leading to decreased central tolerance 
and increased risk of autoimmunity to TSHR.
Supportive of the first mechanism, Brand et al. proposed that 
the TSHR intron 1 GD-associated SNPs regulate mRNA spicing, 
resulting in increased levels of variants encoding a more auto-
antigenic TSHR A-subunit (6). The authors measured the levels 
of full length TSHR (flTSHR) mRNA and of two TSHR truncated 
transcripts named ST4 and ST5 in thyroid tissues of 12 individu-
als and showed that the disease-risk alleles of 2 intron 1 SNPs 
(rs179247 and rs12101255) associate with increased ST4 and 
ST5 and with decreased flTSHR levels. They suggested that the 
truncated ST4 and ST5 variants could be translated into TSHR 
extracellular A-subunit, the main target of TSHR autoantibodies 
(6). However, the mechanisms by which the two SNPs interact 
with TSHR mRNA splicing were not addressed, and the authors 
did not exclude the possibility that other intron 1 SNPs in strong 
LD could also modulate TSHR transcription (53).
The second mechanism by which TSHR intron 1 variants 
could trigger thyroid autoimmunity through defective central 
tolerance was initially proposed by Pujol-Borrell group (37). 
By measuring TSHR mRNA levels in thymus and correlating 
them with the genotype of intron 1 SNPs, Colobran et al. found 
that individuals carrying the disease-protective genotype at the 
rs179247 site have higher levels of thymic TSHR mRNA than 
those with the disease-associated genotype (37). These findings, 
coupled with the fact that negative selection of autoreactive 
thymocytes is dose dependent (54), support the concept that, 
by modulating TSHR transcription, intron 1 disease-associated 
SNPs could modulate negative selection of TSHR-autoreactive 
T cells in the thymus. Thus, decreased TSHR thymic expression 
FiGURe 1 | Thyroid-stimulating hormone receptor (TSHR) intron 1 Graves’ disease (GD)-associated DnA variants. (A) Schematic representation of the 
TSHR gene and the intron 1 GD-associated single nucleotide polymorphisms (SNPs). Black squares represent exons; white bars represent introns; white triangles in 
intron 1 represent the SNPs associated with GD susceptibility; gray bar overlapping the rs12101255 and rs12101261 represent the region characterized by 
H3K4me1 enrichment (47). (B) Proposed model for rs12101261 allele-dependent regulation of TSHR transcription. Upper panel: the presence of the disease-
protective genotype (C/C) at the rs12101261 site prevents strong interactions with promyelocytic leukemia zinc finger protein (PLZF), allowing TSHR transcription; 
lower panel: the presence of the disease-associated genotype (T/T) facilitates binding of PLZF, triggering chromatin folding and interaction with TSHR promoter and 
transcriptional machinery.
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would facilitate the escape of TSHR-reactive T cells from central 
tolerance in genetically susceptible individuals, increasing the 
risk for AITD development. The same group showed that TSHR 
mRNA and protein are expressed in thymocytes from early 
stages of differentiation but are not detected in extra-thymic 
T cells. Moreover, thymic TSHR is functional, and TSAbs from 
GD patients can stimulate thymocytes through this receptor 
(55). Based on these findings, Pujol-Borrell group suggested that 
constant stimulation of thymic TSHR by TSAbs can be a potential 
mechanism explaining thymic hyperplasia, commonly observed 
in GD (55). Furthermore, the authors proposed that continuous 
TSAbs stimulation of thymocytes could lead to improved affinity 
and stimulating capability of TSHR cross-reactive low-affinity 
antibodies due to the interactions between egressing thymocytes 
and B-cells in the lymph nodes or the thyroid gland (55, 56). This 
would result in production of high-affinity TSAbs, the hallmark 
of GD pathogenesis.
Mechanistic insights into the contribution of TSHR intron 1 
SNPs to AITD susceptibility through defective central tolerance 
were recently revealed by studies from Tomer group (47). Their 
work originated from the premise that the disease-associated vari-
ants can specifically interact, through epigenetic modifications, 
with environmental factors to trigger disease susceptibility. To 
reveal the functionality of the GD-associated SNPs, Stefan et al. 
(47) analyzed genome-wide modifications of histone 3 lysine 4 
(K4)-monomethylated (H3K4me1), a chromatin mark often asso-
ciated with distal enhancer elements (57), induced by interferon 
alpha (IFNα), a key cytokine secreted during viral infections, 
previously shown to trigger thyroid autoimmunity (58).
This approach led to identification of an open chromatin region 
marked by IFNα-induced H3K4me1 enrichment overlapping two 
adjacent TSHR intron 1 GD-associated SNPs: rs12101255 and 
rs12101261 (47) (Figure  1A). Functional studies revealed that 
the region overlapping the rs12101261 site harbors a regulatory 
element that functions through binding of the transcriptional 
repressor, promyelocytic leukemia zinc finger protein (PLZF). 
PLZF binding was shown to be restricted at the disease-associated 
variant of the rs12101261 site and was correlated with lower 
thymic TSHR mRNA levels in individuals carrying the disease-
predisposing genotype, as compared with individuals carrying 
the disease-protective genotype. The authors proposed that loss 
of proper genetic–epigenetic interactions due to microenviron-
mental influences, such as sustained IFNα production during 
viral infections, would affect the regulation of TSHR susceptible 
variants resulting in impaired gene expression. In thymus, the 
lower TSHR expression triggered by the susceptible genotype 
would likely facilitate escape from central tolerance and increases 
the risk of autoimmunity to TSHR.
However, the underlying mechanisms by which the cis-
regulatory element at the rs12101261 site modulates TSHR tran-
scription have still to be experimentally addressed. A possible 
regulatory model involves long-range chromatin interactions 
determined by the rs12101261 genotype. In such model, the 
presence of the disease-protective genotype (C/C) would cause 
a weak interaction of PLZF with chromatin at the rs12101261 
site, resulting in active TSHR transcription (Figure  1B, upper 
panel). The presence of the disease-associated genotype (T/T) 
would enable strong PLZF binding at the cis-element, triggering 
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formation of chromatin loops and direct interactions between 
PLZF and TSHR promoter, resulting in inhibition of transcrip-
tion (Figure 1B, lower panel). Thus, allele-dependent differences 
in chromatin folding would trigger allele-dependent differences 
in gene expression. These chromatin interactions, still to be 
experimentally addressed, are likely cell specific, and different 
factors (e.g., TFs) and SNPs may control TSHR expression in 
different tissues.
COnCLUDinG ReMARKS
Studies in the last 15  years established a robust association 
of TSHR gene with GD, and the disease-associated locus was 
recently fine-mapped within 40 kb region in intron 1. Moreover, 
it has become clear that whether TSHR SNPs interfere with gene 
expression in thymus leading to the escape of TSHR-reactive 
T  cells from central tolerance or defects in peripheral toler-
ance are involved, these variants are unlikely to act alone, and 
interactions with epigenetic and environmental factors as well as 
combinatorial effects should be considered.
Although important advances have been made in our under-
standing of the role of TSHR polymorphisms in AITD, questions 
still persist. What are the mechanisms by which TSHR polymor-
phisms predispose to disease? Which are the environmental factors 
that unequivocally contribute to disease development and how they 
interact with susceptible variants? Can genetic variants be translated 
into markers predicting disease development? Does susceptibility 
of epigenetic markers to environmental triggers have a role in the 
functionality of the disease-associated variants? To answer these 
questions, more work and close collaborations of molecular biolo-
gists and clinical scientists as well as more integrated approaches 
are needed. It is hoped that such knowledge would open the road 
toward the development of new, targeted, and preventive therapies 
based on the individual’s particular susceptibility.
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